Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04222829
Other study ID # JS-CT-2019-09
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date December 4, 2019
Est. completion date June 1, 2021

Study information

Verified date August 2022
Source Jaseng Medical Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This study is a prospective, case-control observational trial. The investigators will compare the Megadose Shinbaro Pharmacopuncture group to the control group to analyze the effectiveness of shoulder Megadose Shinbaro Pharmacopuncture.


Description:

Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints. Shinbaro is a refined herbal formulation used to treat inflamed lesions and bone diseases. This treatment is known to be an important part of Korean medicine treatment. However, there has been no specific value for the effect of this treatment. Therefore, The investigators conducted observational trial to analyze the effectiveness of Megadose Shinbaro Pharmacopuncture on shoulder. From Dec 2019, The investigators will collect 80 patients with Chronic shoulder pain on both or each shoulder with the numeric rating scale(NRS) over 4. The investigators will compare pain, dysfunction, quality of life and satisfaction of patients who are treated with Korean medical treatment including Megadose Shinbaro Pharmacopuncture and patients who are treated with Korean medical treatment not including Megadose Shinbaro Pharmacopuncture. For these two groups, The investigators will compare NRS(Numeric Rating Scale), Visual Analogue Scale(VAS), Range Of Motion(ROM), Shoulder Pain and Disability Index(SPADI), Patient Global Impression of Change (PGIC) and EuroQol 5-Dimension (EQ-5D-5L).


Recruitment information / eligibility

Status Terminated
Enrollment 36
Est. completion date June 1, 2021
Est. primary completion date June 1, 2021
Accepts healthy volunteers No
Gender All
Age group 19 Years to 70 Years
Eligibility Inclusion Criteria: - Patients with NRS = 4 for shoulder pain over 3weeks - Patients aged 19-70 years on the date they sign the consent form. - Patients who provide consent to participate in the trial and return the informed consent form Exclusion Criteria: - Patients who have been diagnosed with a severe disease that may cause shoulder pain, - Patients with progressive neurological deficit or with serious neurological symptoms caused by spinal cord compression. - Patients who visited a hospital in pain caused by a traffic accident. - Patients with a severe mental illness. - Patients who are difficult to complete the research participation agreement

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Megadose Shinbaro Pharmacopuncture
Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints. Shinbaro is a refined herbal formulation used to treat inflamed lesions and bone diseases.

Locations

Country Name City State
Korea, Republic of Haeundae Jaseng Hospital of Korean Medicine Busan

Sponsors (1)

Lead Sponsor Collaborator
Jaseng Medical Foundation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Numeric Rating Scale of shoulder pain The extent of shoulder pain and discomfort was assessed using NRS. NRS is a pain scale in which the patient indicates their subjective pain as a whole number from 0 to 10. The participant is asked to report their shoulder pain and discomfort using NRS, where 0 indicates 'no pain or discomfort' and 10 indicates 'the most severe pain and discomfort imaginable'. At 2 weeks
Secondary Visual Analogue Scale of shoulder pain VAS is an assessment index in which the patient records their pain on a 100mm line from 'no pain' at one end, and 'the most severe pain imaginable' at the other end. Higher scores mean a worse outcome At screening, baseline, 2 weeks and through study completion, an average of 3 month
Secondary Shoulder mobility on the Shoulder ROM Shoulder ROM was measured in six directions (Flexion, Extension, Abduction, Adduction, Right rotation, Left rotation) with goniometer. At baseline, 2 weeks and through study completion, an average of 3 month
Secondary Shoulder Pain and Disability Index questionnaire of shoulder pain and disability SPADI is a self-administered questionnaire that consists of two dimensions, one for pain and the other for functional activities. Higher scores mean a worse outcome At baseline, 2 weeks, 3 months
Secondary Patient Global Impression of Change The PGIC is an index that assesses improvements in functional limitation caused by whiplash injury. Participants rate the improvement in functional limitations after treatment on a 7-point Likert scale (1=Very much improved, 4=No change, 7=Very much worse). This index was originally developed for use in Psychology, but is currently used in various other medical fields to assess improvements in pain. At baseline, 2 weeks, 3 months
Secondary EuroQol 5-Dimension The EQ-5D-5L is a method of indirectly calculating the weights of certain health states for quality of life after a multidimensional investigation of health states, and is the most widely used instrument for this purpose. The EQ-5D consists of 5 questions about current health state (mobility, self-care, usual activities, pain, anxiety/depression), and each question is scored on a 5-point Likert scale (1=no problems, 3=moderate problems, 5=severe problems). In this study, The investigators will use the Korean version of the EQ-5D-5L, which has been demonstrated to be valid. At baseline, 2 weeks, 3 months
Secondary Number of Participants with Adverse events Adverse events(AE) Physicians will monitor and record any unexpected or unintended patient reaction to integrative korean medicine at each visit. Adverse events (AEs) associated with integrative korean medicine will include, but not be limited to, AEs anticipated from previous reports of korean medicine, and will stay open to all possibilities taking into consideration other potential, unknown AEs. Through study completion, an average of 3 month
Secondary Numeric Rating Scale of shoulder pain The extent of shoulder pain and discomfort was assessed using NRS. NRS is a pain scale in which the patient indicates their subjective pain as a whole number from 0 to 10. The participant is asked to report their shoulder pain and discomfort using NRS, where 0 indicates 'no pain or discomfort' and 10 indicates 'the most severe pain and discomfort imaginable'. At screening, baseline, 3 months and through study completion, an average of 3 month
See also
  Status Clinical Trial Phase
Completed NCT03270033 - Intravenous Dexmedetomidine, Dexamethasone and Interscalene Block Duration After Arthroscopic Shoulder Surgery Phase 4
Completed NCT04777370 - Combined Effects of Manual Therapy on the Shoulder N/A
Completed NCT04173754 - The Effectiveness of MSAT for Patients With ROM Limitation of the Shoulders
Completed NCT06314321 - The Effect of Baduanjin on Shoulder Function in Maintenance Hemodialysis Patients N/A